- Email: [email protected]
Safety and Efficacy of Concurrent Chemoradiotherapy for Advanced Esophagogastric Junction Squamous Cell Carcinoma
Annals of Oncology 25 (Supplement 5): v75–v109, 2014 doi:10.1093/annonc/mdu436.79
Poster Session (Poster presentations categorized by each organ) P2
5
6
Kiyomi Sumita1, Takahiro Tsushima2, Satoshi Hamauchi2, Akiko Todaka2, Tomoya Yokota2, Nozomu Machida2, Kentaro Yamazaki2, Akira Fukutomi2, Yusuke Onozawa3, Hirofumi Yasui3 1 Division of Radiation Oncology, Shizuoka Cancer Center 2 Division of Gastrointestinal Oncology, Shizuoka Cancer Center 3 Division of Clinical oncology, Shizuoka Cancer Center
abstracts
Background: Esophagogastric junction (EGJ) cancer accounts for 4.2% of all esophageal cancer in Japan, and the outcome of chemoradiotherapy (CRT) for the disease is unclear. Objective: To assess the safety and efficacy of CRT for advanced EGJ squamous cell carcinoma (SCC).
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v92/2240525 by guest on 25 October 2019
SAFETY AND EFFICACY OF CONCURRENT CHEMORADIOTHERAPY FOR ADVANCED ESOPHAGOGASTRIC JUNCTION SQUAMOUS CELL CARCINOMA
Methods: We retrospectively analyzed patients who were treated with definitive CRT for EGJ cancer between September 2002 and September 2013. Patient selection criteria were: pathologically confirmed SCC; clinical Stage IB-III excluding T4 disease (UICC 7th); ECOG performance status (PS), 0-2; preserved organ functions; no previous chemotherapy or radiotherapy; concurrent CRT with 5-FU + platinum and radiation therapy at least 50.0Gy. Results: Nine patients were identified out of 818 who received CRT for esophageal cancer. Patients’ background was: Male, 6; the median age, 67 years (range 56-78). PS 0/1/2, 7/1/1. Siewert types I/II/III, 6/3/0; Stage IB/IIA/IIIA/IIIB/IIIC (UICC 7th), 2/2/ 2/3/0; T 1/2/3, 0/2/7; N 0/1/2/3, 4/2/3/0. As concurrent chemotherapy, 8 patients received CDDP + 5-FU, and 1 received CDGP + 5-FU. The median radiation dose was 60Gy (range 45-60). Eight patients received at least 50Gy of radiation therapy, and 6 patients received 2 cycles of chemotherapy (treatment completion rate was 56%). The reasons for treatment incompletion were: adverse events, 3; and patient’s refusal, 1. Complete response rate was 44% (4/9). Common grade 3 or more adverse events were leukopenia, thrombocytopenia, hyponatremia, and esophagitis (33%, in each). No treatment related death was observed. With median follow-up of 8.5 months, the median progression free survival was 9.2 months (95%CI: 5.0-10.5). Disease progressed in 7 patients: regrowth of persistent primary tumor, 2; lymph node recurrence in irradiated field, 1; distant metastasis, 4. Conclusion: It is suggested that CRT for SCC of EGJ associates with higher adverse events and poorer outcome than that for thoracic esophagus.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Poster Session (Poster presentations categorized by each organ) P2
5
6
Kiyomi Sumita1, Takahiro Tsushima2, Satoshi Hamauchi2, Akiko Todaka2, Tomoya Yokota2, Nozomu Machida2, Kentaro Yamazaki2, Akira Fukutomi2, Yusuke Onozawa3, Hirofumi Yasui3 1 Division of Radiation Oncology, Shizuoka Cancer Center 2 Division of Gastrointestinal Oncology, Shizuoka Cancer Center 3 Division of Clinical oncology, Shizuoka Cancer Center
abstracts
Background: Esophagogastric junction (EGJ) cancer accounts for 4.2% of all esophageal cancer in Japan, and the outcome of chemoradiotherapy (CRT) for the disease is unclear. Objective: To assess the safety and efficacy of CRT for advanced EGJ squamous cell carcinoma (SCC).
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v92/2240525 by guest on 25 October 2019
SAFETY AND EFFICACY OF CONCURRENT CHEMORADIOTHERAPY FOR ADVANCED ESOPHAGOGASTRIC JUNCTION SQUAMOUS CELL CARCINOMA
Methods: We retrospectively analyzed patients who were treated with definitive CRT for EGJ cancer between September 2002 and September 2013. Patient selection criteria were: pathologically confirmed SCC; clinical Stage IB-III excluding T4 disease (UICC 7th); ECOG performance status (PS), 0-2; preserved organ functions; no previous chemotherapy or radiotherapy; concurrent CRT with 5-FU + platinum and radiation therapy at least 50.0Gy. Results: Nine patients were identified out of 818 who received CRT for esophageal cancer. Patients’ background was: Male, 6; the median age, 67 years (range 56-78). PS 0/1/2, 7/1/1. Siewert types I/II/III, 6/3/0; Stage IB/IIA/IIIA/IIIB/IIIC (UICC 7th), 2/2/ 2/3/0; T 1/2/3, 0/2/7; N 0/1/2/3, 4/2/3/0. As concurrent chemotherapy, 8 patients received CDDP + 5-FU, and 1 received CDGP + 5-FU. The median radiation dose was 60Gy (range 45-60). Eight patients received at least 50Gy of radiation therapy, and 6 patients received 2 cycles of chemotherapy (treatment completion rate was 56%). The reasons for treatment incompletion were: adverse events, 3; and patient’s refusal, 1. Complete response rate was 44% (4/9). Common grade 3 or more adverse events were leukopenia, thrombocytopenia, hyponatremia, and esophagitis (33%, in each). No treatment related death was observed. With median follow-up of 8.5 months, the median progression free survival was 9.2 months (95%CI: 5.0-10.5). Disease progressed in 7 patients: regrowth of persistent primary tumor, 2; lymph node recurrence in irradiated field, 1; distant metastasis, 4. Conclusion: It is suggested that CRT for SCC of EGJ associates with higher adverse events and poorer outcome than that for thoracic esophagus.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].